The top 10 biopharma stock gainers and losers for the week.

A quick look back at top stories.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: ARS, Imcheck, Knight, Novartis.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Blueprint Medicines, Hekabio, Nkgen, Sanofi.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Cantargia, Bristol Meyers Squibb, Viatris.

Biopharmas raising money in public or private financings, including: Hemostemix, Mei.

New hires and promotions in the biopharma industry, including: Senti, Sumitomo, Trogenix.

Despite Health and Human Services Secretary Robert Kennedy’s oft-repeated vow to rid the FDA of industry influence, FDA Commissioner Marty Makary announced George Tidmarsh, an industry veteran, will be the next director of the agency’s Center for Drug Evaluation and Research (CDER).

After two decades of research elucidating the basic science, Tafalgie Therapeutics SA has delivered the first clinical data for its non-opioid analgesic.